

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

- Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the quarterly period ended September 30, 2023
- Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission file number: 001-32830



**IGC PHARMA, INC.**

(Exact name of registrant as specified in its charter)

Maryland  
(State or other jurisdiction of incorporation or organization)

20-2760393  
(I.R.S. Employer Identification No.)

10224 Falls Road, Potomac, Maryland  
(Address of principal executive offices)

20854  
(Zip Code)

(301) 983-0998  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.0001 per share	IGC	NYSE American LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No

63,734,439 shares of our common stock were outstanding as of November 7, 2023.



**IGC PHARMA, INC.**  
**FORM 10-Q**  
**FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023**

**Table of Contents**

	<b><u>Page</u></b>
<b>PART I. FINANCIAL INFORMATION</b>	
Item 1.	4
<a href="#">Financial Statements</a>	4
<a href="#">Condensed Consolidated Balance Sheets</a>	4
<a href="#">Condensed Consolidated Statements of Operations and Comprehensive Loss</a>	5
<a href="#">Condensed Consolidated Statements of Changes in Shareholder's Equity</a>	6
<a href="#">Condensed Consolidated Statements of Cash Flows</a>	7
<a href="#">Notes to Condensed Consolidated Financial Statements</a>	8
Item 2.	20
<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	20
Item 3.	28
<a href="#">Quantitative and Qualitative Disclosures About Market Risk</a>	28
Item 4.	28
<a href="#">Controls and Procedures</a>	28
<b>PART II. OTHER INFORMATION</b>	
Item 1.	29
<a href="#">Legal Proceedings</a>	29
Item 1A.	29
<a href="#">Risk Factors</a>	29
Item 2.	29
<a href="#">Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities</a>	29
Item 3.	29
<a href="#">Defaults Upon Senior Securities</a>	29
Item 4.	29
<a href="#">Mine Safety Disclosures</a>	29
Item 5.	30
<a href="#">Other Information</a>	30
Item 6.	30
<a href="#">Exhibits</a>	30
<b><u>SIGNATURES</u></b>	<b>31</b>



## FORWARD-LOOKING STATEMENTS

*This Quarterly Report on Form 10-Q and the documents incorporated herein by reference contain “forward-looking statements.” Additionally, we, or our representatives, may, from time to time, make other written or verbal forward-looking statements and discuss plans, expectations, and objectives regarding our business, financial condition, and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as “believe,” “project,” “expect,” “trend,” “estimate,” “forecast,” “assume,” “intend,” “plan,” “target,” “anticipate,” “outlook,” “preliminary,” “will likely result,” “will continue,” and variations of them and similar terms are intended to be forward-looking statements” as defined by federal securities laws. Such statements are based on currently available information, which management has assessed but which is dynamic and subject to rapid change due to risks and uncertainties that affect our business.*

*For the next several years, we believe our success is highly correlated with the outcome of our clinical trials and secondarily with the sale of our products and services. The Company may not be able to complete human trials on our investigational drug candidate, or, once conducted, the results of human trials may not be favorable or as anticipated or may reflect a lack of efficacy in humans or animals. Precautions, including social distancing and travel restrictions, among others could lead to delays or expenses greater than anticipated or projected. Failure or delay with respect to any of the above factors could have a material adverse effect on our business, future results of operations, stock price, and financial condition.*

*Our projections and investments anticipate certain regulatory changes and stable pricing, which may not hold out over the next several years. We may not be able to protect our intellectual property adequately or receive patents. We may not receive regulatory approval for our products or trials. The patent applications we have licensed may not be granted by the United States Patent and Trademark Office (“USPTO”), even if the Company is in full compliance with USPTO requirements. We may not have adequate resources, including financial resources, to successfully conduct all requisite clinical trials, to bring a product based on the above-referenced patented formulations to market, or to pay applicable maintenance fees over time. We may not be able to successfully commercialize our products even if they are successful and receive regulatory approval, including, but not limited to, based on the Food and Drug Administration’s (“FDA”) current position on hemp and hemp-based products. Failure or delay with respect to any of the factors above could have a material adverse effect on our business, future results of operations, stock price, and financial condition.*

*This document also contains statements that are not approved by the FDA, including statements on hemp and hemp extracts and their potential efficacy on humans and animals. While these statements and claims are intended to be in compliance with federal and state laws, we cannot guarantee such compliance.*

*We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans, and projections subject to risks and uncertainties, including those, if any, identified in the “Risk Factors” set forth in this report or in our annual report on Form 10-K for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on July 7, 2023, which may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements.*



**PART I – FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**IGC Pharma, Inc.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
*(in thousands, except share data)*  
**(Unaudited)**

	<u>September 30,</u> <u>2023</u> <u>(\$)</u>	<u>March 31, 2023</u> <u>(\$)</u>
<b><u>ASSETS</u></b>		
<b>Current assets:</b>		
Cash and cash equivalents	3,026	3,196
Accounts receivable, net	137	107
Short term investments	98	154
Inventory	2,636	2,651
Deposits and advances	220	358
<b>Total current assets</b>	<b>6,117</b>	<b>6,466</b>
<b>Non-current assets:</b>		
Intangible assets, net	1,181	1,170
Property, plant, and equipment, net	7,947	8,213
Claims and advances	998	1,003
Operating lease asset	263	326
<b>Total non-current assets</b>	<b>10,389</b>	<b>10,712</b>
<b>Total assets</b>	<b>16,506</b>	<b>17,178</b>
<b><u>LIABILITIES AND STOCKHOLDERS' EQUITY</u></b>		
<b>Current liabilities:</b>		
Accounts payable	549	530
Accrued liabilities and others	1,557	1,368
<b>Total current liabilities</b>	<b>2,106</b>	<b>1,898</b>
<b>Non-current liabilities:</b>		
Long-term loans	139	141
Other liabilities	17	21
Operating lease liability	146	207
<b>Total non-current liabilities</b>	<b>302</b>	<b>369</b>
<b>Total liabilities</b>	<b>2,408</b>	<b>2,267</b>
<b>Commitments and Contingencies – See Note 12</b>		
<b>Stockholders' equity:</b>		
Preferred stock, \$0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of September 30, 2023, and March 31, 2023.		
Common stock and additional paid-in capital, \$0.0001 par value: 150,000,000 shares authorized; 63,706,939 and 53,077,436 shares issued and outstanding as of September 30, 2023, and March 31, 2023, respectively.	122,732	118,965
Accumulated other comprehensive loss	(3,443)	(3,389)
Accumulated deficit	(105,191)	(100,665)
<b>Total stockholders' equity</b>	<b>14,098</b>	<b>14,911</b>
<b>Total liabilities and stockholders' equity</b>	<b>16,506</b>	<b>17,178</b>

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

**IGC Pharma, Inc.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**  
*(in thousands, except loss per share and share data)*  
**(Unaudited)**

	Three months ended September 30,		Six months ended September 30,	
	2023 (\$)	2022 (\$)	2023 (\$)	2022 (\$)
Revenue	291	202	846	414
Cost of revenue	(117)	(67)	(417)	(137)
<b>Gross profit</b>	<b>174</b>	<b>135</b>	<b>429</b>	<b>277</b>
Selling, General and Administrative expenses	(1,397)	(1,855)	(3,044)	(3,405)
Research and development expenses	(1,268)	(768)	(2,015)	(2,162)
<b>Operating loss</b>	<b>(2,491)</b>	<b>(2,488)</b>	<b>(4,630)</b>	<b>(5,290)</b>
Other income, net	40	46	104	63
<b>Loss before income taxes</b>	<b>(2,451)</b>	<b>(2,442)</b>	<b>(4,526)</b>	<b>(5,227)</b>
Income tax expense/benefit	-	-	-	-
<b>Net loss attributable to common stockholders</b>	<b>(2,451)</b>	<b>(2,442)</b>	<b>(4,526)</b>	<b>(5,227)</b>
Foreign currency translation adjustments	(63)	(182)	(54)	(401)
<b>Comprehensive loss</b>	<b>(2,514)</b>	<b>(2,624)</b>	<b>(4,580)</b>	<b>(5,628)</b>
<b>Net loss per share attributable to common stockholders:</b>				
Basic and diluted	\$ (0.05)	(0.05)	(0.08)	(0.10)
Weighted-average number of shares used in computing net loss per share amounts:	54,301,087	52,194,098	53,695,912	52,082,096

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.



**IGC Pharma, Inc.**  
**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
*(in thousands)*  
**(Unaudited)**

	Number of Common Shares	Common Stock and Additional Paid in Capital (\$)	Accumulated Deficit (\$)	Accumulated Other Comprehensive Loss (\$)	Total Stockholders' Equity (\$)
<b>Three months ended September 30, 2022</b>					
<b>Balances as of June 30, 2022</b>	51,841	117,171	(91,944)	(3,187)	22,040
Common stock-based compensation & expenses, net	1,009	624	-	-	624
Issuance of common stock through offering (net of expenses)	208	104	-	-	104
Cancellation/forfeiture of shares	-	-	-	-	-
Net loss	-	-	(2,442)	-	(2,442)
Foreign currency translation adjustments	-	-	-	(182)	(182)
<b>Balances as of September 30, 2022</b>	<b>53,058</b>	<b>117,899</b>	<b>(94,386)</b>	<b>(3,369)</b>	<b>20,144</b>

<b>Three months ended September 30, 2023</b>					
<b>Balances as of June 30, 2023</b>	53,077	119,322	(102,740)	(3,380)	13,202
Common stock-based compensation & expenses, net	1,130	550	-	-	550
Issuance of common stock through offering (net of expenses)	10,000	2,860	-	-	2,860
Cancellation/forfeiture of shares	(500)	-	-	-	-
Net loss	-	-	(2,451)	-	(2,451)
Foreign currency translation adjustments	-	-	-	(63)	(63)
<b>Balances as of September 30, 2023</b>	<b>63,707</b>	<b>122,732</b>	<b>(105,191)</b>	<b>(3,443)</b>	<b>14,098</b>

	Number of Common Shares	Common Stock and Additional Paid in Capital (\$)	Accumulated Deficit (\$)	Accumulated Other Comprehensive Loss (\$)	Total Stockholders' Equity (\$)
<b>Six months ended September 30, 2022</b>					
<b>Balances as of March 31, 2022</b>	51,054	116,019	(89,159)	(2,968)	23,892
Common stock-based compensation & expenses, net	1,796	1,776	-	-	1,776
Issuance of common stock through offering (net of expenses)	208	104	-	-	104
Cancellation/forfeiture of shares	-	-	-	-	-
Net loss	-	-	(5,227)	-	(5,227)
Foreign currency translation adjustments	-	-	-	(401)	(401)
<b>Balances as of September 30, 2022</b>	<b>53,058</b>	<b>117,899</b>	<b>(94,386)</b>	<b>(3,369)</b>	<b>20,144</b>

<b>Six months ended September 30, 2023</b>					
<b>Balances as of March 31, 2023</b>	53,077	118,965	(100,665)	(3,389)	14,911
Common stock-based compensation & expenses, net	1,130	907	-	-	907
Issuance of common stock through offering (net of expenses)	10,000	2,860	-	-	2,860
Cancellation/forfeiture of shares	(500)	-	-	-	-
Net loss	-	-	(4,526)	-	(4,526)
Foreign currency translation adjustments	-	-	-	(54)	(54)
<b>Balances as of September 30, 2023</b>	<b>63,707</b>	<b>122,732</b>	<b>(105,191)</b>	<b>(3,443)</b>	<b>14,098</b>

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

**IGC Pharma, Inc.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
*(in thousands)*  
(Unaudited)

	Six months Ended September 30,	
	2023 (\$)	2022 (\$)
<b>Cash flows from operating activities:</b>		
<b>Net loss</b>	<b>(4,526)</b>	<b>(5,227)</b>
<i>Adjustment to reconcile net loss to net cash:</i>		
Depreciation and amortization	313	332
Common stock-based compensation and expenses, net	907	1,776
Other non-cash items	(52)	45
<i>Changes in:</i>		
Accounts receivables, net	(30)	(65)
Inventory	15	(202)
Deposits and advances	76	534
Claims and advances	5	(13)
Accounts payable	19	(524)
Accrued and other liabilities	185	(535)
Operating lease asset	63	63
Operating lease liability	(61)	(66)
<b>Net cash used in operating activities</b>	<b>(3,086)</b>	<b>(3,882)</b>
<b>Cash flow from investing activities:</b>		
Purchase of property, plant, and equipment	(55)	277
Sale of property, plant, and equipment	42	-
Investment in short term investments	128	(193)
Acquisition and filing cost of patents and rights	(48)	(60)
<b>Net cash provided by investing activities</b>	<b>67</b>	<b>24</b>
<b>Cash flows from financing activities:</b>		
Net proceeds from the issuance of common stock	2,860	103
Repayment of long-term loan	(2)	(2)
<b>Net cash provided by financing activities</b>	<b>2,858</b>	<b>101</b>
Effects of exchange rate changes on cash and cash equivalents	(9)	(80)
<b>Net decrease in cash and cash equivalents</b>	<b>(170)</b>	<b>(3,837)</b>
Cash and cash equivalents at the beginning of the period	3,196	10,460
<b>Cash and cash equivalents at the end of the period</b>	<b>3,026</b>	<b>6,623</b>
<b>Supplementary information:</b>		
<b>Non-cash items:</b>		
Common stock issued/granted for stock-based compensation, including patent acquisition	907	1,776

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

**IGC Pharma, Inc.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**THREE MONTHS AND SIX MONTHS ENDED SEPTEMBER 30, 2023**  
**(in thousands, except for share data and loss per share, unaudited)**

*Unless the context requires otherwise, all references in this report to “IGC,” “the Company,” “we,” “our” and/or “us” refer to IGC Pharma, Inc., together with our subsidiaries and beneficially owned subsidiary. Our public filings with the Securities and Exchange Commission, the “SEC,” are available on [www.sec.gov](http://www.sec.gov). The information contained on our various websites, including [www.igcinc.us](http://www.igcinc.us), is not incorporated by reference in this report, and you should not consider such information to be a part of this report. We exclude our investments and minority non-controlling interests, and any information provided by them is not incorporated by reference in this report, and you should not consider such information to be a part of this report.*

**NOTE 1 – BUSINESS DESCRIPTION**

**Overview**

IGC Pharma is a clinical-stage pharmaceutical company developing novel therapies for Alzheimer’s disease and conditions related to the central nervous system. The company is pursuing five assets: IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, all of which target Alzheimer’s disease and are at various stages of development.

Our most clinically advanced investigational new drug for Alzheimer’s, IGC-AD1, has shown significant promise in preclinical studies. In Alzheimer’s cell lines, IGC-AD1 has demonstrated the potential to effectively suppress or ameliorate two key hallmarks of Alzheimer’s disease: plaques and tangles. In animal models, it has shown effectiveness in improving memory. Furthermore, in a Phase 1 multiple ascending dose (MAD) trial, it exhibited potential efficacy in reducing neuropsychiatric symptoms, including agitation, anxiety, and depression. IGC-AD1 is currently in a Phase 2B, multi-center, randomized, double-blind, placebo-controlled trial, specifically designed to address agitation in dementia from Alzheimer’s disease ([clinicaltrials.gov](http://clinicaltrials.gov), NCT05543681). This condition affects more than 10 million individuals in North America and Europe. The trial is being conducted at 10 sites in the US and Canada.

Our portfolio includes four other small molecule assets, each at distinct stages of development, all with a singular mission — to transform the landscape of Alzheimer’s treatment. LMP targets neuroinflammation, A $\beta$  plaques, and neurofibrillary tangles, TGR-63 targets A $\beta$  plaque, where we seek to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of A $\beta$  plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles, IGC-1C represents a forward-thinking approach to Alzheimer’s therapy.

Furthermore, IGC controls a total of 36 patent filings. IGC maintains a state-of-the-art manufacturing facility in Washington State, which is poised for potential use in a Phase 3 trial and commercialization of IGC-AD1. In Bogota, Colombia, we also operate an R&D laboratory and an internal Contract Research Organization (CRO) that provides clinical trial services. We are actively expanding our technological capabilities with a primary focus on Generative Artificial Intelligence (AI) to enhance various aspects of clinical trial operations and data analysis. Our Company is investing in and driving AI development with an immediate focus on clinical trial processes, and analysis. Our AI initiatives are centered on informing clinical trials, developing a methodology for early detection of Alzheimer’s, and investigating the interaction of pharmaceuticals with cannabinoids.

Collectively, these core assets and initiatives underscore our commitment to advancing the field of pharmaceuticals, delivering groundbreaking treatments, and creating lasting value for our investors. We remain steadfast in our pursuit of excellence and our mission to improve the lives of those affected by Alzheimer’s and related conditions.

Our manufacturing facility is also utilized to produce women’s wellness products under the brand “Holief.” IGC Pharma is a Maryland corporation established in 2005 with a fiscal year ending on March 31, spanning a 52- or 53-week period. The company operates in two primary business segments: Life Sciences and Infrastructure.

**Life Sciences Segment**

***Pharmaceutical:*** Since 2014, the Company has focused primarily on the potential uses of phytocannabinoids, in combination with other compounds, to treat multiple diseases, such as Alzheimer’s disease. As a company engaged in the clinical-stage pharmaceutical industry, we focus our research and development efforts, subject to results of future clinical trials, on seeking pharmaceutical solutions that may a) alleviate neuropsychiatric symptoms such as agitation, anxiety, and depression associated with dementia in Alzheimer’s disease; and b) halt the onset, progression, or cure Alzheimer’s disease.





***Over-the-Counter Products:*** We have created a women’s wellness brand, Holief™, available through online channels that are compliant with relevant federal, state, and local laws and regulations. Holief™ is an all-natural, non-GMO, vegan, line of over-the-counter (OTC) products aimed at treating menstrual cramps (dysmenorrhea) and premenstrual syndrome (PMS). The products are available online and through Amazon and other online channels. In addition, we white label our product formulations to other companies that market them under their brand.

### ***Phase 2 Clinical Trial Update***

In this document, we use the terms Phase 2 and Phase 2B interchangeably, though typically, a Phase 2 trial is divided into a Phase 2A and a Phase 2B trial. Phase 2A is designed to assess dosing requirements, while Phase 2B is intended to establish efficacy. Our company has started a Phase 2B protocol called “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease.” The trial is powered at 146 Alzheimer’s patients, with half receiving a placebo, and is a superior, parallel-group study.

The primary end point is agitation in dementia due to Alzheimer’s disease, as rated by the Cohen-Mansfield Agitation Inventory (CMAI) over a six-week period. The Phase 2 trial will also look at eleven exploratory objectives, including changes in anxiety, changes in cognitive processes such as attention, orientation, language, and visual spatial skills as well as memory, changes in depression, delusions, hallucinations, euphoria/elation, apathy, disinhibition, irritability, aberrant motor behavior, sleep disorder, appetite, quality of life, and caregiver burden. In addition, the trial will evaluate the impact of CYP450 polymorphisms and specifically CYP2C9 on each of the NPS and assess any reductions in psychotropic drugs, among others. CYP2C9 ranks amongst the most important drug metabolizing enzymes in humans, as it breaks down over 100 drugs, including nonsteroidal anti-inflammatory drugs. We seek to understand how various versions of the enzyme act on IGC-AD1. Each participant will receive two doses of IGC-AD1 (b.i.d.) or two doses of placebo per day for six weeks.

### **Infrastructure Segment**

The Company’s infrastructure business has been operating since 2008. It includes (i) execution of construction contracts and (ii) rental of heavy construction equipment.

### **Business Organization**

As of September 30, 2023, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), IGCare LLC, Holi Hemp LLC, IGC Pharma LLC, SAN Holdings LLC, Sunday Seltzer LLC, Hamsa Biopharma India Pvt. Ltd., Colombia-based beneficially-owned subsidiary IGC Pharma SAS (formerly Hamsa Biopharma Colombia SAS) and IGC Pharma IP LLC. The Company’s fiscal year is the 52- or 53-week period that ends on March 31. The Company’s principal office is in Maryland. Additionally, the Company has offices in Washington state, Colombia, and India. The Company’s filings are available on [www.sec.gov](http://www.sec.gov). IGC Pharma, Inc. was incorporated in 2005.

## **NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

### **Basis of presentation**

The accompanying condensed consolidated Balance Sheet as of September 30, 2023, and March 31, 2023, condensed consolidated statements of operations for the three months and six months ended September 30, 2023, and 2022, and condensed consolidated statements of cash flows for the six months ended September 30, 2023, and 2022, are unaudited. The consolidated balance sheet as of March 31, 2023, has been derived from audited financial statements, and the accompanying as of September 30, 2023 unaudited condensed consolidated financial statements (“interim statements”) of the Company have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (the “FASB”) within its Accounting Standards Codification (“ASC”) and under the rules and regulations of the SEC.

Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these interim statements have been included. The results reported in these interim statements are not necessarily indicative of the results that may be reported for the entire year. These interim statements should be read in conjunction with the Company’s audited consolidated financial statements for the fiscal year ended March 31, 2023 (“Fiscal 2023”) contained in the Company’s Form 10-K for Fiscal 2023, filed with the SEC on July 7, 2023, specifically in Note 2 to the consolidated financial statements.



## Principles of consolidation

The interim statements include the consolidated accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated. In the opinion of Management, the interim statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its subsidiaries are eliminated in the consolidated financial statements.

## Presentation and functional currencies

The Company operates in India, the U.S., Colombia, and Hong Kong, and a portion of the Company's financials are denominated in the Indian Rupee ("INR"), the Hong Kong Dollar ("HKD"), or the Colombian Peso ("COP"). As a result, changes in the relative values of the U.S. Dollar ("USD"), the INR, the HKD, or the COP affect our financial statements.

The accompanying financial statements are reported in USD. INR, HKD, and COP are the functional currencies for certain subsidiaries of the Company. The translation of the functional currencies into USD is performed for assets and liabilities using the exchange rates in effect at the balance sheet date and for revenues and expenses using average exchange rates prevailing during the reporting periods. Adjustments resulting from the translation of functional currency financial statements to reporting currency are accumulated and reported as other comprehensive (loss), a separate component of shareholders' equity. Transactions in currencies other than the functional currency during the year are converted into the functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the consolidated statements of operations.

## Going Concern

The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, "*Presentation of Financial Statements—Going Concern*", which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.

The Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses and negative cash flows from operations in the near future.

The Company estimates that its current cash and cash equivalents balance with working capital credit facility and equity investment is sufficient to support operations beyond the twelve months following the date these consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.

## Accounts receivable

We make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required. We had \$137 thousand of accounts receivable, net of provision for the doubtful debt of \$12 thousand as of September 30, 2023, as compared to \$107 thousand of accounts receivable, net of provision for the doubtful debt of \$17 thousand as of March 31, 2023.

## Loss per share

The computation of basic loss per share for the six months ended September 30, 2023, excludes potentially dilutive securities of approximately 9 million shares, which includes share options, unvested shares such as restricted shares and restricted share units, granted to employees, non-employees, and advisors, and shares from the conversion of outstanding units, if any because their inclusion would be anti-dilutive.

The weighted average number of shares outstanding for the six months ended September 30, 2023, and 2022, used for the computation of basic earnings per share ("EPS") is 53,695,912 and 52,082,096, respectively, as compared to 54,301,087 and 52,194,098 for the three months ended September 30, 2023, and 2022, respectively. Due to the loss incurred by the Company during the six months ended September 30, 2023, and 2022, all the potential equity shares are anti-dilutive, and accordingly, the fully diluted EPS is equal to the basic EPS.



## Cybersecurity

We have a cybersecurity policy in place and have taken cybersecurity measures to safeguard against hackers, however, there can be no assurance thereof. During the six months ended September 30, 2023, there were no impactful breaches in cybersecurity.

## Revenue Recognition

The Company recognizes revenue under ASC 606, *Revenue from Contracts with Customers* (ASC 606). The core principle of this standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

ASC 606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales as follows:

- I. Identify the contract with the customer.
- II. Identify the contractual performance obligations.
- III. Determine the amount of consideration/price for the transaction.
- IV. Allocate the determined amount of consideration/price to the performance obligations.
- V. Recognize revenue when or as the performing party satisfies performance obligations.

The consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the services and products in the Infrastructure and Life Sciences segment.

Revenue in the Infrastructure segment is recognized for the renting business when the equipment is rented, and the terms of the agreement have been fulfilled during the period. Revenue from the execution of infrastructure contracts is recognized based on the output method as and when part of the performance obligation has been completed, and approval from the contracting agency has been obtained after survey of the performance completion as of that date. In the Life Sciences segment, the revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer and the performance obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or to the customer directly. Revenue from white label services is recognized when the performance obligation has been completed, and output material has been transferred to the customer.

Net sales disaggregated by significant products and services for the three months and six months ended September 30, 2023, and 2022 are as follows:

	<i>(in thousands)</i> <i>Three months</i> <i>ended</i> <i>September 30,</i> <i>2023</i> <i>(\$)</i>	<i>(in thousands)</i> <i>Three months</i> <i>ended</i> <i>September 30,</i> <i>2022</i> <i>(\$)</i>	<i>(in thousands)</i> <i>Six months</i> <i>ended</i> <i>September 30,</i> <i>2023</i> <i>(\$)</i>	<i>(in thousands)</i> <i>Six months</i> <i>ended</i> <i>September 30,</i> <i>2022</i> <i>(\$)</i>
<b>Infrastructure segment (1)</b>	-	7	166	17
<b>Life Sciences segment</b>				
Wellness and lifestyle (2)	69	150	113	230
White labeling services (3)	222	45	567	167
<b>Total</b>	<b>291</b>	<b>202</b>	<b>846</b>	<b>414</b>

(1) Infrastructure segment consists of income from the rental of heavy construction equipment and construction contracts.

(2) Revenue from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, beverages, hemp crude extract, hemp isolate, and hemp distillate.

(3) Revenue from white label services consists of rebranding our formulations or the customer's products as per the customer's requirement.

## Recently issued accounting pronouncements

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to the FASB's Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs not listed are expected to have no impact on the Company's consolidated financial position and results of operations, because either the ASU is not applicable, or the impact is expected to be immaterial.



**NOTE 3 – INVENTORY**

	<i>(in thousands)</i>	
	As of September 30, 2023	As of March 31, 2023
	(\$)	(\$)
Raw materials	2,127	2,100
Work-in-Progress	11	18
Finished goods	498	533
<b>Total</b>	<b>2,636</b>	<b>2,651</b>

During the six months ended September 30, 2023, and 2022, the Company wrote off approximately \$3 thousand and \$40 thousand of inventory due to abnormal loss due to idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was recorded in Selling, General, and Administrative Expenses.

We capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative use for the inventory in future research and development projects or other purposes. As of September 30, 2023, and March 31, 2023, our consolidated balance sheet reported approximately \$397 thousand and \$407 thousand clinical trial-related inventory, respectively.

**NOTE 4 – DEPOSITS AND ADVANCES**

	<i>(in thousands)</i>	
	As of September 30, 2023	As of March 31, 2023
	(\$)	(\$)
Advances to suppliers and consultants	62	72
Other receivables and deposits	15	24
Prepaid expenses and other current assets	143	262
<b>Total</b>	<b>220</b>	<b>358</b>

The Advances to suppliers and consultants primarily relate to advances to vendors. Prepaid expenses and other current assets include approximately \$25 thousand of statutory advances as of September 30, 2023, and March 31, 2023, respectively.

**NOTE 5 – INTANGIBLE ASSETS**

	<i>(in thousands)</i>	
	As of September 30, 2023	As of March 31, 2023
	(\$)	(\$)
<i>Amortized intangible assets</i>		
Patents	730	709
Other intangibles	34	34
Accumulated amortization	(144)	(107)
<b>Total amortized intangible assets</b>	<b>620</b>	<b>636</b>
<i>Other intangible assets</i>		
Patents	561	534
Other intangibles	-	-
<b>Total unamortized intangible assets</b>	<b>561</b>	<b>534</b>
<b>Total intangible assets</b>	<b>1,181</b>	<b>1,170</b>

[Table of Contents](#)

The value of intangible assets includes the cost of acquiring patent rights, supporting data, and the expense associated with filing of patent applications. It also includes acquisition costs related to domains and licenses.

The intangible with finite life is up to 20 years are amortized on straight-line basis, commencing from the date of grant or acquisition. The amortization expense in the three months ended September 30, 2023, and 2022, amounted to approximately \$18 thousand and \$14 thousand, respectively, whereas the amortization expense in the six months ended September 30, 2023, and 2022 amounted to approximately \$36 thousand and \$24 thousand, respectively.

The Company regularly reviews its intangible assets to determine if any intangible asset is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period and concluded that, as of September 30, 2023, there was no impairment.

	<i>(in thousands)</i>
<b>Estimated annual amortization expense</b>	<b>(\$)</b>
For the year ended 2025	80
For the year ended 2026	89
For the year ended 2027	97
For the year ended 2028	107
For the year ended 2029	118

**NOTE 6 – PROPERTY, PLANT, AND EQUIPMENT**

	<i>(in thousands, except useful life)</i>		
	Useful Life	As of September 30, 2023	As of March 31, 2023
	(years)	(\$)	(\$)
Land	N/A	4,051	4,100
Buildings and facilities	25	2,303	2,298
Plant and machinery	5-20	3,332	3,335
Computer equipment	3	155	138
Office equipment	3-5	99	84
Furniture and fixtures	5	93	92
Vehicles	5	101	102
<b>Total gross value</b>		<b>10,134</b>	<b>10,149</b>
Less: Accumulated depreciation		(2,187)	(1,936)
<b>Total property, plant, and equipment, net</b>		<b>7,947</b>	<b>8,213</b>

The depreciation expense in the three months ended September 30, 2023, and 2022 amounted to approximately \$140 thousand and \$156 thousand, respectively. The depreciation expense in the six months ended September 30, 2023, and 2022 amounted to approximately \$277 thousand and \$308 thousand, respectively. The net decrease in Total property, plant, and equipment is primarily due to depreciation. During the six months ended September 2023, the Company sold a fully depreciated property in India for net proceeds of approximately \$43 thousand and accounted the same in other income. For more information, please refer to Note 16 – “Segment Information” for the non-current assets other than financial instruments held in the country of domicile and foreign countries.

**NOTE 7 – LEFT BLANK INTENTIONALLY**



**NOTE 8 – CLAIMS AND ADVANCES**

	<i>(in thousands)</i>	
	As of September 30, 2023	As of March 31, 2023
	(\$)	(\$)
Claims receivable (1)	947	951
Non-current deposits	26	27
Non-current advances	25	25
<b>Total</b>	<b>998</b>	<b>1,003</b>

- (1) The claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings. It includes \$140 thousand owed to the company by one of our manufacturers for the equipment purchase.

**NOTE 9 – LEFT BLANK INTENTIONALLY****NOTE 10 – ACCRUED AND OTHER LIABILITIES**

	<i>(in thousands)</i>	
	As of September 30, 2023	As of March 31, 2023
	(\$)	(\$)
Compensation and other contributions	749	619
Provision for expenses	378	258
Short-term lease liability	130	133
Other current liability	300	358
<b>Total</b>	<b>1,557</b>	<b>1,368</b>

Compensation and other contribution-related liabilities consist of accrued salaries to employees. In addition, provision for expenses includes provision for legal, professional, and marketing expenses. Other current liability also includes statutory payables of approximately \$37 thousand and \$31 thousand as of September 30, 2023, and March 31, 2023, respectively, and approximately \$3 thousand of short-term loans as of September 30, 2023, and March 31, 2023, respectively.

**NOTE 11 – LOANS AND OTHER LIABILITIES**

*Loan as of September 30, 2023:*

On June 11, 2020, the Company received an Economic Injury Disaster Loan (“EIDL”) for approximately \$150 thousand at an annual interest rate of 3.75%. The Company must pay principal and interest payments of \$731 every month beginning June 5, 2021. The SBA will apply each installment payment first to pay interest accrued to the day the SBA receives the payment and will then apply any remaining balance to reduce the principal. All remaining principal and accrued interest is due and payable 30 years from the date of the loan. For the six months ended September 30, 2023, the interest expense and principal payment for the EIDL were approximately \$3 thousand and \$2 thousand, respectively. For the six months ended September 30, 2022, the interest expense and principal payment for the EIDL were approximately \$2 thousand each. As of September 30, 2023, approximately \$139 thousand of the loan is classified as Long-term loans and approximately \$3 thousand as Short-term loans.



On June 30, 2023, the Company entered into a Master Loan and Security Agreement with O-Bank, CO., LTD. (the “Credit Agreement”), pursuant to which the Company may borrow up to \$12 million, which will be used to fulfill liquidity requirements and ensure the Company’s ability to sustain its operations. The Credit Agreement matures June 30, 2024, with an option to renew. Interest on borrowings will be calculated according to the interest rate stated in the Certificate of Deposit (as defined in the Credit Agreement), plus an applicable margin of 1%, and the Company will bear the tax. The Company must pay the interest in full on the last business day of each interest period. As of September 30, 2023, the Company has not yet used any of the \$12 million available under the Credit Agreement.

*Other Liability:*

	<i>(in thousands)</i>	
	As of	
	September 30, 2023	March 31, 2023
	(\$)	(\$)
Statutory reserve	17	21
<b>Total</b>	<b>17</b>	<b>21</b>

The statutory reserve is a gratuity reserve for employees in our subsidiaries in India.

#### NOTE 12 – COMMITMENTS AND CONTINGENCIES

The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the condensed consolidated financial statements as of September 30, 2023, except as disclosed in the legal proceedings section below.

In the U.S., we provide health insurance, life insurance, and a 401(k) plan wherein the Company matches up to 6% of the employee’s pre-tax contribution up to a maximum annual amount determined by the IRS. In accordance with applicable laws of foreign countries, the Company provides for gratuity, a defined benefit retirement plan (“Gratuity Plan”) covering certain categories of employees. The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee’s last drawn salary and the years of employment with the Company. In addition, employees receive benefits from a provident fund, a defined contribution plan. The employee and employer each make monthly contributions to the plan as required by the law. The contribution is made to the Foreign Government’s funds.

#### NOTE 13 – SECURITIES

As of September 30, 2023, the Company was authorized to issue up to 150,000,000 shares of common stock, par value \$0.0001 per share, and 63,706,939 shares of common stock were issued and outstanding. The Company is also authorized to issue up to 1,000,000 shares of preferred stock, par value \$0.0001 per share, and no preferred shares were issued and outstanding as of September 30, 2023.

Our common stock is listed on the NYSE American (ticker symbol: IGC). This security also trades on the Frankfurt, Stuttgart, and Berlin stock exchanges (ticker symbol: IGS1). The Company also has 91,472 units outstanding that can be separated into common stock. Ten units may be separated into one share of common stock. The unit holders are requested to contact the Company or our transfer agent, Continental Stock Transfer and Trust, to separate their units into common stock.

Pursuant to the December 18, 2014, Purchase Agreement with Apogee, we issued Apogee 1.2 million shares of IGC’s common stock valued at \$888 thousand for the purchase of a 24.9% ownership interest in Midtown Partners & Co., LLC (MTP). During Fiscal 2018, after considering several factors, the Company concluded that it no longer had significant influence over MTP and maintained the same investment value of approximately \$773 thousand. During Fiscal 2020, the Company created a provision for this investment. The Company initiated the litigation on February 8, 2021, against Apogee. During the three months ended September 2023, the court’s ruling on the motion for summary judgment, the parties participated in a mediation where they agreed in principle to a settlement as to all claims against each other. As per the summary judgement, Apogee returned 500 thousand of Company’s shares back and Company cancelled the shares. For more information, kindly refer to Item 1 – Legal Proceedings for more information.



On October 27, IGC Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common stock, par value \$0.0001 per share (the “Common Stock”), having an aggregate offering price of up to \$60 million (“Shares”), subject to certain limitations on the amount of Common Stock that may be offered and sold by the Company set forth in the Sales Agreement (the “Offering”). Prior to entering into the Sales Agreement with A.G.P./Alliance Global Partners, the Company terminated the Sales Agreement dated January 13, 2021, with The Benchmark Company.

**NOTE 14 – STOCK-BASED COMPENSATION**

As of September 30, 2023, 9 million restricted share units (RSUs), fair valued at \$5.7 million with a weighted average value of \$0.64 per share, have been granted but not yet issued from different Incentive Plans and Grants. This includes 4.7 million RSUs granted to employees and directors, which consists of a vesting schedule based entirely on the attainment of both operational milestones and market conditions, assuming continued employment either as an employee or director with the Company. The performance-based RSUs are accounted upon certification by Management, confirming the probability of achievement of milestones. As of September 30, 2023, Management confirmed three of the milestones had been achieved, and the rest were considered probable to be achieved by March 31, 2028.

Additionally, options held by advisors and directors to purchase 150 thousand shares of common stock fair valued at \$69 thousand with a weighted average of \$0.46 per share have been granted but are to be exercised over a service period ending in Fiscal 2031. Options exercised before the service period are expensed when exercised.

The options are valued using a Black-Scholes Pricing Model and Market based RSUs are valued based on a lattice model, with the following assumptions:

	Granted in Fiscal 2024	Granted in Fiscal 2023
Expected life of options	5 years	5 years
Vested options	100%	100%
Risk-free interest rate	3.49%	2.64%
Expected volatility	280%	285%
Expected dividend yield	Nil	Nil

The expense associated with share-based payments to employees, directors, advisors, and contractors is allocated over the vesting or service period and recognized in the Selling, General, and Administrative expenses (including research and development). For the six months ended September 30, 2023, the Company’s share-based expense and option-based expense shown in Selling, General and Administrative expenses (including research and development) were \$901 thousand and \$6 thousand, respectively, and for the six months ended September 30, 2022, the Company’s share-based expense and option-based expense was \$1.8 million and \$17 thousand, respectively.

	Shares (in thousands) (#)	Weighted average grant date fair value (\$)
<b>Non-vested shares</b>		
Non-vested shares as of March 31, 2023	4,429	1.01
Granted	4,300	0.26
Vested	(197)	0.30
Cancelled/forfeited	-	-
<b>Non-vested shares as of September 30, 2023</b>	<b>8,532</b>	<b>0.65</b>

	Shares (in thousands) (#)	Weighted average grant date fair value (\$)	Weighted average exercise price (\$)
<b>Options</b>			
Options outstanding as of March 31, 2023	150	1.39	0.30
Granted	-	-	-
Exercised	-	-	-
Cancelled/forfeited	-	-	-
<b>Options outstanding as of September 30, 2023</b>	<b>150</b>	<b>1.39</b>	<b>0.30</b>



There was a combined unrecognized expense of \$2.7 million related to non-vested shares and share options that the Company expects to be recognized over the weighted average life of 5 years.

**NOTE 15 – FAIR VALUE OF FINANCIAL INSTRUMENTS**

As of September 30, 2023, the Company’s investments may consist of money market funds, debt and equity funds, and other marketable securities, among others, which have been classified as Level 1 of the fair value hierarchy because they have been valued using quoted prices in active markets. The Company’s cash and cash equivalents have also been classified as Level 1 on the same principle. Financial instruments are classified as current if they are expected to be liquidated within the next twelve months. The Certificates of Deposit are classified as Level 2 as they do not have regular market pricing, but their fair value can be determined based on other data values or market prices. The Company’s remaining investments have been classified as Level 3 instruments as there is little or no market data. Level 3 investments are valued using the cost method.

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2023, and March 31, 2023, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:

*(in thousands)*

*As of September 30, 2023*

<b>Particular</b>	<b>Adjusted Cost (\$)</b>	<b>Gain (\$)</b>	<b>Loss (\$)</b>	<b>Fair Value (\$)</b>	<b>Cash &amp; Cash Equivalents (\$)</b>	<b>Short Term Investments (\$)</b>
<b>Level 1</b>						
Cash	939	-	-	939	939	-
Money Market Fund	1,828	-	-	1,828	1,828	-
Debt Funds	13	1	-	13	13	-
Mutual Fund	153	15	-	168	70	98
<b>Level 2</b>						
Certificates of Deposit	176	-	-	176	176	-
<b>Level 3</b>						
	-	-	-	-	-	-
<b>TOTAL</b>	<b>3,109</b>	<b>16</b>		<b>3,124</b>	<b>3,026</b>	<b>98</b>

*As of March 31, 2023*

<b>Particular</b>	<b>Adjusted Cost (\$)</b>	<b>Gain (\$)</b>	<b>Loss (\$)</b>	<b>Fair Value (\$)</b>	<b>Cash &amp; Cash Equivalents (\$)</b>	<b>Short Term Investments (\$)</b>
<b>Level 1</b>						
Cash	1,156	-	-	1,156	1,156	-
Money Market Fund	2,000	-	-	2,000	2,000	-
Debt Funds	40	-	-	40	40	-
Mutual Fund	152	2	-	154	-	154
<b>Level 2</b>						
Certificates of Deposit	-	-	-	-	-	-
<b>Level 3</b>						
	-	-	-	-	-	-
<b>TOTAL</b>	<b>3,348</b>	<b>2</b>		<b>3,350</b>	<b>3,196</b>	<b>154</b>



**NOTE 16 – SEGMENT INFORMATION**

FASB ASC 280, “Segment Reporting,” establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group (CODM), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on our integration and Management strategies, we operate in two reportable segments, the (i) Infrastructure segment and (ii) Life Sciences segment.

The Company’s CODM is the Company’s Chief Executive Officer (CEO). The CEO reviews financial information presented on an operating segment basis for purposes of making operating decisions and assessing financial performance. Therefore, and before our Life Sciences segment started, the Company determined that it operated in a single operating and reportable segment. As of the date of this report and in preparation for the new and different source of revenue, the Company has determined that it operates in two operating and reportable segments, the (a) Infrastructure segment and (b) Life Sciences segment. The Company does not include intercompany transfers between segments for Management reporting purposes.

The following provides information required by ASC 280-10-50-38 “Entity-wide Information”:

1) The table below shows revenue reported by segment:

	<i>(in thousands)</i> <i>Three months</i> <i>ended</i> <i>September 30,</i> <i>2023</i> <i>(\$)</i>	<i>(in thousands)</i> <i>Three months</i> <i>ended</i> <i>September 30,</i> <i>2022</i> <i>(\$)</i>	<i>(in thousands)</i> <i>Six months</i> <i>ended</i> <i>September 30,</i> <i>2023</i> <i>(\$)</i>	<i>(in thousands)</i> <i>Six months</i> <i>ended</i> <i>September 30,</i> <i>2022</i> <i>(\$)</i>
<b>Infrastructure segment</b>	-	7	166	17
<b>Life Sciences segment</b>				
Wellness and lifestyle	69	150	113	230
White labeling services	222	45	567	167
<b>Total</b>	<b>291</b>	<b>202</b>	<b>846</b>	<b>414</b>

For information on revenue by product and service, refer to Note 2, “Summary of Significant Accounting Policies”.

2) The table below shows the revenue attributed to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the geographic location of customers:

<b>Segments</b>	<b>Country</b>	<i>(in thousands)</i>	
		<b>Three months ended</b> <b>September 30, 2023</b> <b>(\$)</b>	<b>Six months ended</b> <b>September 30, 2023</b> <b>(\$)</b>
Asia	India	-	166
America	U.S.	291	680
<b>Total</b>		<b>291</b>	<b>846</b>

<b>Segments</b>	<b>Country</b>	<i>(in thousands)</i>	
		<b>Three months ended</b> <b>September 30, 2022</b> <b>(\$)</b>	<b>Six months ended</b> <b>September 30, 2022</b> <b>(\$)</b>
Asia	India	7	17
America	U.S.	195	397
<b>Total</b>		<b>202</b>	<b>414</b>

3) The table below shows the non-current assets other than financial instruments held in the country of domicile (U.S.) and foreign countries.

Nature of assets	<i>(in thousands)</i>		Total as of September 30, 2023
	USA (Country of Domicile)	Foreign Countries (India, Hong Kong, and Colombia)	
	(\$)	(\$)	(\$)
Intangible assets, net	1,181	-	1,181
Property, plant, and equipment, net	3,855	4,092	7,947
Claims and advances	588	410	998
Operating lease asset	247	16	263
<b>Total non-current assets</b>	<b>5,871</b>	<b>4,518</b>	<b>10,389</b>

Nature of assets	<i>(in thousands)</i>		Total as of March 31, 2023
	USA (Country of Domicile)	Foreign Countries (India, Hong Kong, and Colombia)	
	(\$)	(\$)	(\$)
Intangible assets, net	1,170	-	1,170
Property, plant, and equipment, net	4,074	4,139	8,213
Claims and advances	585	418	1,003
Operating lease asset	298	28	326
<b>Total non-current assets</b>	<b>6,127</b>	<b>4,585</b>	<b>10,712</b>

**NOTE 17 – SUBSEQUENT EVENTS**

- On October 8, 2023, the European Intellectual Property Office issued a patent (#3193862) to the Company titled “CANNABINOID COMPOSITION AND METHOD FOR TREATING PAIN”. The granted patent introduces a pioneering method for treating pain in humans. Utilizing a cream base infused with a unique blend of cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD), alongside other compounds, this revolutionary cream or gel is designed for transdermal absorption. It interacts harmoniously with the peripheral nervous and immune systems, delivering effective pain relief without psychotropic or adverse side effects.
- On October 27, IGC Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common stock, par value \$0.0001 per share (the “Common Stock”), having an aggregate offering price of up to \$60 million (“Shares”), subject to certain limitations on the amount of Common Stock that may be offered and sold by the Company set forth in the Sales Agreement (the “Offering”). Prior to entering into the Sales Agreement with A.G.P./Alliance Global Partners, the Company terminated the Sales Agreement dated January 13, 2021, with The Benchmark Company.



## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The purpose of this Management's Discussion and Analysis ("MD&A") is to provide an understanding of IGC Pharma, Inc.'s ("IGC," the "Company," "we," "our," and/or "us") consolidated financial condition and results of operations and cash flows. The MD&A should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the three months and six months ended September 30, 2023, and the Annual Report on Form 10-K for the fiscal year ended March 31, 2023, filed with the SEC on July 7, 2023 (the "2023 Form 10-K"). The Company's actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the "Forward-Looking Statements" and "Risk Factors" sections and discussed elsewhere in this report. The risks and uncertainties can cause actual results to differ significantly from those in our forward-looking statements or implied in historical results and trends. Accordingly, we caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as expressly required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those outlined in the forward-looking statements.

### Overview

IGC Pharma is a clinical-stage pharmaceutical company developing novel therapies for Alzheimer's disease and conditions related to the central nervous system. The company is pursuing five assets: IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, all of which target Alzheimer's disease and are at various stages of development.

Our most clinically advanced investigational new drug for Alzheimer's, IGC-AD1, has shown significant promise in preclinical studies. In Alzheimer's cell lines, IGC-AD1 has demonstrated the potential to effectively suppress or ameliorate two key hallmarks of Alzheimer's disease: plaques and tangles. In animal models, it has shown effectiveness in improving memory. Furthermore, in a Phase 1 multiple ascending dose (MAD) trial, it exhibited potential efficacy in reducing neuropsychiatric symptoms, including agitation, anxiety, and depression. IGC-AD1 is currently in a Phase 2B, multi-center, randomized, double-blind, placebo-controlled trial, specifically designed to address agitation in dementia from Alzheimer's disease (clinicaltrials.gov, NCT05543681). This condition affects more than 10 million individuals in North America and Europe. The trial is being conducted at 10 sites in the US and Canada.

Our portfolio includes four other small molecule assets, each at distinct stages of development, all with a singular mission — to transform the landscape of Alzheimer's treatment. LMP targets neuroinflammation, A $\beta$  plaques, and neurofibrillary tangles, TGR-63 targets A $\beta$  plaque, where we seek to disrupt the progression of Alzheimer's disease. IGC-M3 targets the inhibition of A $\beta$  plaque aggregation with the potential to create a profound impact on early-stage Alzheimer's. IGC-1C targets tau and neurofibrillary tangles, IGC-1C represents a forward-thinking approach to Alzheimer's therapy.

Furthermore, IGC controls a total of 36 patent filings. IGC maintains a state-of-the-art manufacturing facility in Washington State, which is poised for potential use in a Phase 3 trial and commercialization of IGC-AD1. In Bogota, Colombia, we also operate an R&D laboratory and an internal Contract Research Organization (CRO) that provides clinical trial services. The Company is actively expanding its technological capabilities with a primary focus on Generative Artificial Intelligence (AI) to enhance various aspects of operations including clinical research and clinical trials. Our company is investing in and driving AI development with a strong focus on transforming our approach, gaining insights, and increasing cost efficiencies. Our AI initiatives are centered on informing clinical trials, developing a methodology for early detection of Alzheimer's, and investigating the interaction of pharmaceuticals with cannabinoids.

Collectively, these core assets and initiatives underscore our commitment to advancing the field of pharmaceuticals, delivering groundbreaking treatments, and creating lasting value for our investors. We remain steadfast in our pursuit of excellence and our mission to improve the lives of those affected by Alzheimer's and related conditions.

Our manufacturing facility is also utilized to produce women's wellness products under the brand "Holief." IGC Pharma is a Maryland corporation established in 2005 with a fiscal year ending on March 31, spanning a 52- or 53-week period. The company operates in two primary business segments: Life Sciences and Infrastructure.

### Life Sciences Segment

*Pharmaceutical:* Since 2014, the Company has focused primarily on the potential uses of phytocannabinoids, in combination with other compounds, to treat multiple diseases, such as Alzheimer's disease. As a company engaged in the clinical-stage pharmaceutical industry, we focus our research and development efforts, subject to results of future clinical trials, on seeking pharmaceutical solutions that may a) alleviate neuropsychiatric symptoms such as agitation, anxiety, and depression associated with dementia in Alzheimer's disease; and b) halt the onset, progression, or cure Alzheimer's disease.



Currently, IGC-AD1 is in a Phase 2B safety and efficacy clinical trial for agitation in dementia from Alzheimer's (clinicaltrials.gov, NCT05543681). The progress we are making in the clinical trial, gives us confidence in the potential of IGC-AD1 as a potentially groundbreaking therapy, with the potential to treat Alzheimer's and to manage devastating symptoms that separate families, increase admissions to nursing homes, and drive the cost of Alzheimer's care, although there can be no assurance.

Although there can be no assurance, we believe that additional investment in clinical trials, research, and development (R&D), facilities, marketing, advertising, AI and acquisition of complementary products and businesses supporting our Life Sciences segment will be critical to the development and delivery of innovative products and positive patient and customer experiences. We hope to leverage our R&D and intellectual property to develop ground-breaking, science-based products that are proven effective through planned pre-clinical and clinical trials. Although there can be no assurance, we believe this strategy has the potential to improve existing products and lead to the creation of new products, which, based on scientific study and research, may offer positive results for the management of certain conditions, symptoms, and side effects.

While the bulk of our medium and longer-term focus is on clinical trials and getting IGC-AD1 into an FDA-approved drug, our shorter-term strategy is to use our resources to provide white-label services and market Holief™. We believe this may provide us with several profit opportunities, although there can be no assurance of such profit opportunities.

*Over-the-Counter Products:*

We have created a women's wellness brand, Holief™, available through online channels that are compliant with relevant federal, state, and local laws and regulations. Holief™ is an all-natural, non-GMO, vegan, line of over-the-counter (OTC) products aimed at treating menstrual cramps (dysmenorrhea) and premenstrual syndrome (PMS). The products are available online and through Amazon and other online channels. In addition, we sell our product formulations to other companies that market them under their brand. This is the white label part of the OTC business.

*Contract Research Organization (CRO) and Clinical Trial Software:*

The IGC-Pharma Electronic Data Capture system (IGC-EDC) is a secure and user-friendly data management software designed to collect clinical trial data in electronic format. The software incorporates rigorous security measures that help IGC to protect data and ensure compliance with regulatory requirements and industry standards. This format is designed for our clinical trials, especially our Phase 2 trial. The EDC system is designed to store and organize handwritten source documents, including medical history, concomitant medications, laboratory results, neuropsychiatric scales scores, adverse events, vital signs, safety calls, demographics, among others. The system allows users to generate data reports that will be used for data analysis and generate computational models to simulate the effects of our investigational drug IGC-AD1 on participants' outcomes. At IGC Pharma, we recognize the significance of operational excellence and cost management in clinical trials. One major cost driver in conducting trials is the expense associated with engaging CROs. These costs can significantly impact on the overall budget of a trial. To address this challenge and optimize trial costs, we have established an internal CRO, including proprietary software that we believe sets us apart from the traditional approach of outsourcing. We believe this strategic move will enable us to reduce the costs associated with clinical trials compared to relying on external CROs, although there can be no assurance.

On July 21, 2023, IGC Pharma and the University of Los Andes (Faculty of Engineering) signed a Master Cooperation Agreement, to conduct innovative research in AI applied to the pharmaceutical industry and to join efforts to create academic spaces that allow for generating research and development projects and innovation. This agreement will enable us to work closely with some of the brightest minds in the field and develop innovative projects. We are excited to collaborate with the University of Los Andes and are committed to advancing the frontiers of science and technology together. We believe this overlay of Artificial Intelligence (AI) will help us simulate trial scenarios, generate new insights to facilitate improved decision-making, efficiently design our Phase 3 trial, provide advanced data analysis, and ultimately enhance the effectiveness and efficiency of our clinical trials, although there can be no assurance thereof. Our AI initiatives are centered on enhancing clinical trials, developing a methodology for early detection of Alzheimer's, and investigating the interaction of pharmaceuticals with cannabinoids. By leveraging AI technology, we aim to accelerate progress in Alzheimer's drug development and revolutionize the way we approach treatment. We believe that our commitment to advancing the field of AI in medicine creates a strategic advantage in the industry, although there can be no assurance thereof.



## Infrastructure Segment

The Company's infrastructure business has been operating since 2008. It includes (i) execution of construction contracts and (ii) rental of heavy construction equipment.

### Company Highlights for the Quarter ended September 30, 2023

- The Company has increased its revenue by 44% compared to the same period in 2022. During the three months ended September 30, 2023, the Company generated \$291 thousand in revenue.
- On July 21, 2023, IGC Pharma and the University of Los Andes (Faculty of Engineering) signed a Master Cooperation Agreement to conduct innovative research in AI applied to the pharmaceutical industry and to join efforts to create academic spaces that allow for generating research and development projects and innovation.
- On July 11, 2023, the Canadian Intellectual Property Office issued a patent (#2,961,410) to the Company titled "CANNABINOID COMPOSITION AND METHOD FOR TREATING PAIN". The patent relates to compositions and methods for treating multiple types of seizure disorders in humans using a combination of cannabinoids with other compounds. Subject to further research and study, the combination may be used for relieving pain in patients with psoriatic arthritis, fibromyalgia, scleroderma, shingles, and related pain-generating conditions.

## Business Strategy

The Life Sciences business strategy includes:

1. Subject to FDA approval, developing IGC-AD1 as a drug for treating agitation in dementia due to Alzheimer's and investigating and developing TGR-63, LMP, IGC-1C and IGC -M3 for the potential treatment of Alzheimer's disease.
2. Marketing Holief™ and formulations.

We believe developing a drug for both symptom and disease-modifying agents has less risk due to the need for expensive multi-year trials. However, there is considerable upside and significant value creation to the extent we obtain a first-in-class advantage, of which there can be no assurance. If we were to obtain a first-in-class advantage, such an advantage could result in significant growth if and when an approved drug such as IGC-AD1 launches.

We believe that additional investment in clinical trials, AI, research and development (R&D), facilities, marketing, advertising, and acquisition of complementary products and businesses will be critical to the ongoing growth of the Life Sciences segment. Although there can be no assurance, we believe these investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our R&D and intellectual property to develop ground-breaking, science-based products that are proven effective through clinical trials, subject to FDA approval. Although there can be no assurance, we believe this strategy can improve our existing products and lead to the creation of new products that can provide treatment options for multiple conditions, symptoms, and side effects.



**Results of Operations for the Three Months Ended****September 30, 2023, and September 30, 2022**

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the three months ended September 30, 2023, and September 30, 2022:

*Statement of Operations (in thousands, unaudited)*

	<b>Three months ended September 30,</b>		<b>Change</b>	<b>Percent Change</b>
	<b>2023</b>	<b>2022</b>		
	(\$)	(\$)	(\$)	
Revenue	291	202	89	44%
Cost of revenue	(117)	(67)	(50)	75%
<b>Gross profit</b>	<b>174</b>	<b>135</b>	<b>39</b>	<b>29%</b>
Selling, General and Administrative expenses	(1,397)	(1,855)	458	(25)%
Research and development expenses	(1,268)	(768)	(500)	65%
<b>Operating loss</b>	<b>(2,491)</b>	<b>(2,488)</b>	<b>(3)</b>	<b>-%</b>
Other income, net	40	46	(6)	(13)%
<b>Loss before income taxes</b>	<b>(2,451)</b>	<b>(2,442)</b>	<b>(9)</b>	<b>-%</b>
Income tax expense/benefit	-	-	-	-
<b>Net loss</b>	<b>(2,451)</b>	<b>(2,442)</b>	<b>(9)</b>	<b>-%</b>

*Revenue* – During the three months ended September 30, 2023, the Company generated approximately \$291 thousand in revenue, representing an increase of approximately \$89 thousand, or 44%, compared to the approximately \$202 thousand recorded during the three months ended September 30, 2022. The primary source of revenue in both quarters was from the Life Sciences segment, encompassing the sales of our formulations as white-labeled manufactured products and sales of branded holistic women’s health care products, among others. The Infrastructure segment revenue was nil and approximately \$7 thousand for the three months ended September 30, 2023, and September 30, 2022, respectively.

*Cost of revenue* – Cost of revenue amounted to approximately \$117 thousand for the three months ended September 30, 2023, compared to \$67 thousand in the three months ended September 30, 2022, this represents gross margins of 60% to 67%, respectively. The cost of revenue is primarily attributable to the cost of raw materials, labor, and other direct overheads required to produce our products in the Life Science segment. Typically, the gross margin in the Life Sciences business will fluctuate from one quarter to another based on the mix within the Life Science business between white label, private label, and branded products. There is insufficient revenue to model or project gross margins.

*Selling, General and Administrative expenses (“SG&A”)* – SG&A expenses primarily encompass various costs such as employee-related expenses, sales commissions, professional fees, legal fees, marketing expenses, other corporate expenses, allocated general overhead, provisions, depreciation, and write-offs related to doubtful accounts and advances. During the three months ended September 30, 2023, SG&A expenses decreased by approximately \$458 thousand or 25% to approximately \$1.4 million, from approximately \$1.9 million recorded for the three months ended September 30, 2022. The decrease in SG&A expenses is attributed to a decrease in operational and corporate expenses.

*Research and Development expenses* – R&D expenses were attributed to our Life Sciences segment. The R&D expenses increased by approximately \$500 thousand or 65% to \$1.3 million during the three months ended September 30, 2023, from approximately \$768 thousand for the three months ended September 30, 2022. The increase is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on the other small molecule assets. Although there can be no assurance, we anticipate increased R&D expenses as the development of our other small molecule assets targeting Alzheimer’s and the Phase 2B trial on Alzheimer’s expand.

*Other income, net* – Other net income decreased by approximately \$6 thousand or 13% during the three months ended September 30, 2023. The total other income for the three months ended September 30, 2023, and 2022, is approximately \$40 thousand and \$46 thousand, respectively. The component of other income typically includes interest and rental income, dividend income, profits from the sale of assets, unrealized gains from non-debt investments, net income, and income from the sale of scraps. These sources contribute to the overall other income generated by the Company.



**Results of Operations for the Six Months Ended September 30, 2023, and September 30, 2022**

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the six months ended September 30, 2023, and September 30, 2022:

*Statement of Operations (in thousands, unaudited)*

	<b>Six months ended September 30,</b>		<b>Change</b>	<b>Percent</b>
	<b>2023</b>	<b>2022</b>		
	<b>(\$)</b>	<b>(\$)</b>	<b>(\$)</b>	<b>Change</b>
Revenue	846	414	432	104%
Cost of revenue	(417)	(137)	(280)	204%
<b>Gross profit</b>	<b>429</b>	<b>277</b>	<b>152</b>	<b>55%</b>
Selling, General and Administrative expenses	(3,044)	(3,405)	361	(11)%
Research and development expenses	(2,015)	(2,162)	147	(7)%
<b>Operating loss</b>	<b>(4,630)</b>	<b>(5,290)</b>	<b>660</b>	<b>(12)%</b>
Other income, net	104	63	41	65%
<b>Loss before income taxes</b>	<b>(4,526)</b>	<b>(5,227)</b>	<b>701</b>	<b>(13)%</b>
<b>Income tax expense/benefit</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Net loss</b>	<b>(4,526)</b>	<b>(5,227)</b>	<b>701</b>	<b>(13)%</b>

*Revenue* – Revenue was approximately \$846 thousand and \$414 thousand for the six months ended September 30, 2023, and September 30, 2022, respectively. Revenue in both quarters was primarily derived from our Life Sciences segment, which involved providing white-label manufactured products and sales of holistic women’s health care products, among others. The Infrastructure segment revenue was approximately \$166 thousand and \$17 thousand for the six months ended September 30, 2023, and September 30, 2022, respectively. The increase in revenue derived from the Infrastructure segment relates to the completion of a construction contract. The Company remains committed to its current strategy of driving sales in formulations both as branded and white-labeled products in the Life Science segment.

*Cost of revenue* – Cost of revenue amounted to approximately \$417 thousand for the six months ended September 30, 2023, compared to \$137 thousand in the six months ended September 30, 2022, this represents gross margins of 51% and 67%, respectively. The cost of revenue is primarily attributable to the cost of raw materials, labor, and other direct overheads required to produce our products in the Life Science segment. The decrease in gross margin is reflective of a change in the mix of revenue between Infrastructure and Life Science. Typically, the gross margin in the Life Sciences business, while higher than in the infrastructure, will fluctuate from one quarter to another based on the mix within the Life Science business between white label, private label, and branded products.

*Selling, General and Administrative expenses* – SG&A expenses were approximately \$3 million and \$3.4 million for the six months ended September 30, 2023, and September 30, 2022, respectively. The decrease of \$361 thousand is attributed to a decrease in operational and corporate expenses. SG&A expenses consist primarily of employee-related expenses, sales commission, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation, and write-offs relating to doubtful accounts, and advance, if any.

*Research and Development expenses* – R&D expenses were attributed to our Life Sciences segment. The R&D expenses decreased by approximately \$147 thousand or 7% to \$2 million during the six months ended September 30, 2023, from approximately \$2.1 million during the six months ended September 30, 2022. The decrease is primarily attributable to the reduction of non-cash expenses due to achievement of performance-based milestone.

*Other income, net* – Other net income increased by approximately \$41 thousand or 65% during the six months ended September 30, 2023. As a result, the total other income for the six months ended September 30, 2023, and 2022 is approximately \$104 thousand and \$63 thousand, respectively. The increase in other income for the six months ended September 30, 2023, is attributable to profit from the sale of assets. Other income includes interest and rental income, dividend income, profit from the sale of assets, unrealized gains from investments, net income, and income from scrap sales.





**Liquidity and Capital Resources**

Our sources of liquidity are cash and cash equivalents, funds raised through the ATM offering, cash flows from operations, short-term and long-term borrowings, and short-term liquidity arrangements. The Company continues to evaluate various financing sources and options to raise working capital to help fund current research and development programs and operations. The Company does not have any material long-term debt, capital lease obligations, or other long-term liabilities except as disclosed in this report. Please refer to Note 12, “Commitments and contingencies,” and Note 11, “Loans and Other Liabilities,” in Item 1 of this report for further information on Company commitments and contractual obligations.

On June 30, 2023, the Company signed the Master Loan and Security Agreement (the “Credit Agreement”) with O-Bank, CO., LTD. pursuant to which the Company may borrow up to \$12 million. Additionally, the Company sold 10 million shares of common stock for \$3 million pursuant to an SPA with Bradbury Asset Management and three unrelated investors. These measures have been taken to address ongoing liquidity requirements and ensure the Company’s ability to sustain its operations. Moreover, the Company plans to raise additional funds through private placement and ATM offerings, subject to market conditions, although there can be no assurance that such financing efforts will be successful.

The Credit Agreement matures on June 30, 2024, with an option to renew. Borrowings under the Credit Agreement will bear interest, calculated according to the interest rate mentioned in the Certificate of Deposit (as defined in the Credit Agreement), as the case may be, plus an applicable margin of 1%, and the Company shall bear the tax. Interest is due and payable in full by the Company on the last business day of each interest period. As of September 30, 2023, the entire amount of \$12 million remains unused.

On October 27, IGC Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of its common stock, par value \$0.0001 per share (the “Common Stock”), having an aggregate offering price of up to \$60 million (“Shares”), subject to certain limitations on the amount of Common Stock that may be offered and sold by the Company set forth in the Sales Agreement (the “Offering”). Prior to entering into the Sales Agreement with A.G.P./Alliance Global Partners, the Company terminated the Sales Agreement dated January 13, 2021, with The Benchmark Company.

The Company expects to raise further capital for its research and development initiatives as and when it is able to do so, but there can be no assurance thereof. In addition, there can be no assurance of the terms thereof, and any subsequent equity financing sought may have dilutive effects on our current shareholders. While there is no guarantee that we will be successful, we are applying to non-dilutive funding opportunities such as Small Business Research and Development programs. In addition, subject to limitations on the amount of capital that can be raised, the Company expects to utilize its shelf registration on a statement on Form S- 3 to raise capital through at-the-market offerings or otherwise.

Please refer to Item 1A. “Risk Factors” of our Form 10-K for the fiscal year ended March 31, 2023, for further information on the risks related to the Company.

	<i>(in thousands, unaudited)</i>			
	As of September 30, 2023 (\$)	As of March 31, 2023 (\$)	Change	Percent Change
Cash and cash equivalents	3,026	3,196	(170)	(5)%
Working capital	4,011	4,568	(557)	(12)%

*Cash and cash equivalents*

Cash and cash equivalents decreased by approximately \$170 thousand to \$3 million in the six months ended September 30, 2023, from \$3.2 million as of March 31, 2023, a decrease of approximately 5%.



Summary of Cash flows

	<i>(in thousands, unaudited)</i>		Change	Percent Change
	Six months ended September 30,			
	2023	2022		
Cash used in operating activities	(3,086)	(3,882)	796	(21)%
Cash provided by investing activities	67	24	43	179%
Cash provided by financing activities	2,858	101	2,757	2,730
Effects of exchange rate changes on cash and cash equivalents	(9)	(80)	71	89%
<b>Net decrease in cash and cash equivalents</b>	<b>(170)</b>	<b>(3,837)</b>	<b>3,667</b>	<b>(96)%</b>
Cash and cash equivalents at the beginning of period	3,196	10,460	(7,264)	(69)%
<b>Cash and cash equivalents at the end of the period</b>	<b>3,026</b>	<b>6,623</b>	<b>(3,597)</b>	<b>(54)%</b>

Operating Activities

Net cash used in operating activities for the six months ended September 30, 2023, was approximately \$3.1 million. It consists of a net loss of approximately \$4.5 million, a positive impact on cash due to non-cash expenses of approximately \$1.1 million, and a positive change in operating assets and liabilities of approximately \$272 thousand. Non-cash expenses consist of an amortization and depreciation charge of approximately \$313 thousand, stock-based expenses of approximately \$907 thousand, and an approximately \$52 thousand decrease in other non-cash items. In addition, changes in operating assets and liabilities had a positive impact of approximately \$272 thousand on cash, of which approximately \$30 thousand is due to a decrease in accounts receivables, approximately \$19 thousand increase in accounts payable, approximately \$185 thousand increase in accrued and other liabilities and approximately \$98 thousand increase in other net current assets and liabilities.

Net cash used in operating activities for the six months ended September 30, 2022, was approximately \$3.8 million. It consists of a net loss of approximately \$5.2 million, a positive impact on cash due to non-cash expenses of approximately \$2.2 million, and a negative change in operating assets and liabilities of approximately \$808 thousand. Non-cash expenses consist of an amortization/depreciation charge of approximately \$332 thousand, stock-based expenses of approximately \$1.8 million, and net loss on the sale of a fixed asset of approximately \$45 thousand. In addition, changes in operating assets and liabilities had a negative impact of approximately \$808 thousand on cash, of which approximately \$65 thousand is due to a decrease in accounts receivables, approximately \$524 thousand decrease in accounts payable, and approximately \$219 thousand decrease in other net current assets and liabilities.

Investing Activities

Net cash provided by investing activities for the six months ended September 30, 2023, was approximately \$67 thousand, which comprised of expenses of approximately \$48 thousand for the acquisition filing expenses related to intellectual property, approximately \$13 thousand for the net purchase of property, plant, and equipment and approximately \$128 thousand of investment in marketable securities.

Net cash provided by investing activities for the six months ended September 30, 2022, was approximately \$24 thousand, which comprised proceeds from the sale of property, plant, and equipment of approximately \$277 thousand, adjusted with cash expenses of approximately \$60 thousand for the acquisition and filing expenses related to patents and approximately \$193 thousand of a short-term investment.

Financing Activities

Net cash provided by financing activities was approximately \$2.8 million for the six months ended September 30, 2023, which is comprised of net proceeds from issuance of equity stock of approximately \$2.8 million and re-payment of the loan of approximately \$2 thousand.

Net cash provided by financing activities from the issuance of equity stock through our 2021 ATM offering, net of all expenses related to the issuance of stock, was approximately \$101 thousand and re-payment of the loan of approximately \$2 thousand for the six months ended September 30, 2022.



## **Off-Balance Sheet Arrangements**

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions, or foreign currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity, or market risk support to such entity. We do not have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk, or credit support to us or that engages in leasing, hedging, or research and development services with us.

## **Critical Accounting Policies**

While all accounting policies impact financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require management's most subjective or complex judgments and estimates. Our management believes the policies that fall within this category are the policies on revenue recognition, inventory, accounts receivable, foreign currency translation, impairment of long-lived assets and investments, stock-based compensation, and cybersecurity.

Please see our disclosures in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report, in the Notes to the Audited Consolidated Financial Statements in the 2023 Form 10-K, as well as Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations in the 2023 Form 10-K, for a discussion of all our critical and significant accounting policies.

## **Recent Accounting Pronouncements**

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to the FASB's Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs not listed are expected to have no impact on the Company's consolidated financial position and results of operations because either the ASU is not applicable, or the impact is expected to be immaterial. Recent accounting pronouncements that may apply to us are described in Note 2, "Significant Accounting Policies" to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report and in the Notes to the Audited Consolidated Financial Statements in Part II of our 2023 Form 10-K.



### **Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Item 3 does not apply to us because we are a smaller reporting company.

### **Item 4. Controls and Procedures**

#### ***Evaluation of Disclosure Controls and Procedures***

Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Management, including our Chief Executive Officer (our principal executive officer) and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

Our Management, including the Chief Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods specified in SEC rules and forms and that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

#### ***Changes in Internal Control over Financial Reporting***

Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during the three months ended September 30, 2023, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during the three months ended September 30, 2023, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.



## PART II – OTHER INFORMATION

### Item 1. Legal Proceedings

The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

As of September 30, 2023, the Company and one of its officers are parties to the following litigation matter:

**Apogee Financial Investments, Inc., et al. v. India Globalization Capital, Inc., et al., Civil Action No. 1:21-cv-03809 (U.S. District Court for the Southern District of New York).** On April 29, 2021, Apogee Financial Investments, Inc. (Apogee) and John R. Clarke (Clarke) filed a complaint against the Company and IGC's President and Chief Executive Officer, Ram Mukunda (Mukunda) (the Apogee Litigation). The litigation was originally initiated by IGC on February 8, 2021 (India Globalization Capital, Inc. v. Apogee Financial Investments, Inc., Civil Action No. 1:21-cv-01131, U.S. District Court for the Southern District of New York), wherein IGC alleged that Apogee breached a purchase agreement dated December 18, 2014, related to IGC's intended purchase of a business known as Midtown Partners & Co., LLC (Midtown). In response to the original lawsuit filed by IGC, Apogee and Clarke filed a counterclaim as well as the Apogee Litigation. On June 28, 2021, Apogee and Clarke filed an amended complaint/counterclaim. On July 23, 2021, IGC and Mukunda moved to partially dismiss the counterclaim and the Apogee Litigation. On March 7, 2022, the Court granted the motion to dismiss in substantial part, leaving only two claims: Apogee's cross-claim against the Company for an alleged breach of the purchase agreement; and Clarke's claim against the Company for an alleged breach of an alleged promise to issue him shares of the Company. On June 24, 2022, Apogee and Clarke filed a second amended complaint/counterclaim asserting the same claims. On February 21, 2023, IGC and Mukunda filed a motion for summary judgment seeking judgment on both IGC's underlying Complaint against Apogee and Apogee's and Clarke's claims against Apogee and Mukunda. On April 19, 2023, Apogee and Clarke filed a response to the motion. Both Apogee and Clarke withdrew their claims against Mukunda at that time. The Company filed its reply in support of summary judgment on May 16, 2023. On July 20, 2023, the court granted the motion for summary judgment in substantial part, ruling (a) that Apogee breached the parties' purchase agreement, (b) that Clarke's claims were barred by the applicable statute of limitations, (c) that Apogee breached a contract related to a loan made by IGC to Apogee in 2015 and that IGC is entitled to damages and interest as a result; and (d) that all claims against Mukunda are dismissed. As a result of the settlement, the court dismissed the case in its entirety on October 6, 2023.

### Item 1A. Risk Factors

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

### Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

As previously disclosed, on June 30, 2023, the Company entered into an SPA with Bradbury Asset Management and three unrelated investors, resulting in approximately \$3 million in gross proceeds. The completion of the private placement was subject to customary closing conditions, including approval by the NYSE. The shares were issued on September 25, 2023.

Under the terms of the private placement, IGC issued 10 million shares of unregistered common stock at a price of \$0.30 per share. Shares are intended to be exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), by virtue of the provisions of Section 4(a)(2) of the Securities Act and Regulation D and/or Regulation S adopted thereunder.

### Item 3. Defaults Upon Senior Securities

None.

### Item 4. Mine Safety Disclosures

Not applicable.



**Item 5. Other Information**

None.

**Item 6. Exhibits**

<b>Exhibit Number</b>	<b>Exhibit Description</b>
3.1	<a href="#">Amended and Restated Articles of Incorporation of the Registrant, as amended on August 1, 2012 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on August 6, 2012).</a>
3.2	<a href="#">Articles of Amendment to the Company's Amended and Restated Articles of Incorporation filed with the State Department of Assessments and Taxation of Maryland on March 7, 2023 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on March 21, 2023).</a>
3.3	<a href="#">By-laws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company's Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).</a>
3.4	<a href="#">Amendment to the Amended and Restated Articles of Incorporation of the Registrant as amended on August 2, 2014 (incorporated by reference to Exhibit 3.3 to the Company's Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).</a>
3.5	<a href="#">Amendment to the Bylaws of the Company dated March 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on March 21, 2023).</a>
31.1*	<a href="#">Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.</a>
31.2*	<a href="#">Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer.</a>
32.1**	<a href="#">Certifications pursuant to 18 U.S.C. §1350.</a>
101.INS*	Inline XBRL Instance Document.
101.SCH*	Inline XBRL Taxonomy Extension Schema Document.
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document.
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

\* Filed herewith.

\*\* Furnished herewith.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**IGC PHARMA, INC.**

Date: November 9, 2023

By: /s/ Ram Mukunda  
Ram Mukunda  
President and Chief Executive Officer  
(Principal Executive Officer)

Date: November 9, 2023

By: /s/ Claudia Grimaldi  
Claudia Grimaldi  
Vice-president & Chief Compliance Officer  
(Principal Financial Officer)



**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 17 CFR 240.13(a)-14(a)  
(SECTION 302 CERTIFICATION)**

I, Ram Mukunda, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IGC Pharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The Registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The Registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023

By: /s/ Ram Mukunda  
Ram Mukunda  
President and Chief Executive Officer  
(Principal Executive Officer)



**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 17 CFR 240.13(a)-14(a)  
(SECTION 302 CERTIFICATION)**

I, Claudia Grimaldi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of IGC Pharma, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The Registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The Registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023

By: /s/ Claudia Grimaldi  
Claudia Grimaldi  
Vice-president & Chief Compliance Officer  
(Principal Financial Officer)

**Exhibit 32.1**

**CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350  
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Ram Mukunda, certify, as of the date hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of IGC Pharma, Inc. on Form 10-Q for the period ended September 30, 2023, (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of IGC Pharma, Inc. at the dates and for the periods indicated.

Date: November 9, 2023

By: /s/ Ram Mukunda  
Ram Mukunda  
Chief Executive Officer and President  
(Principal Executive Officer)

I, Claudia Grimaldi, certify, as of the date hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of IGC Pharma, Inc. on Form 10-Q for the period ended September 30, 2023, (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of IGC Pharma, Inc. at the dates and for the periods indicated.

Date: November 9, 2023

By: /s/ Claudia Grimaldi  
Claudia Grimaldi  
Vice-president & Chief Compliance Officer  
(Principal Financial Officer)